CA-074: Selective Cathepsin B Inhibitor for Cancer and Neurotoxicity Research

Executive Summary: CA-074 is a potent, selective cathepsin B inhibitor with a Ki of 2–5 nM, demonstrating >10,000-fold selectivity over cathepsins H and L. CA-074 blocks cathepsin B–mediated proteolytic cascades implicated in cancer metastasis, neurotoxicity, and immune regulation (Liu et al., 2023, https://doi.org/10.1038/s41418-023-01237-7). In vivo, it reduces bone metastasis in breast cancer models without impacting primary tumor growth. CA-074 has negligible cytotoxicity at 10 mM in cell culture and is soluble in DMSO, ethanol, and water. The compound is validated for dissecting cathepsin B–dependent pathways in regulated cell death and immune modulation (APExBIO).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in intracellular protein degradation and extracellular matrix remodeling. Its dysregulation is implicated in tumor invasion, metastasis, and neurodegeneration. Lysosomal membrane permeabilization (LMP) releases cathepsin B, which then drives cell death and inflammatory responses (Liu et al., 2023). In cancer, cathepsin B promotes metastasis by degrading extracellular barriers. In the CNS, microglial cathepsin B contributes to neurotoxicity in response to amyloid beta (Abeta42). Cathepsin B also modulates immune responses by regulating Th-2/Th-1 balance and antibody production. Selective inhibition of cathepsin B is a validated strategy for dissecting these pathways in preclinical and translational models (internal reference).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a reversible, competitive inhibitor of cathepsin B. Its chemical name is (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid, molecular weight 383.44 g/mol. The compound binds the active site of cathepsin B, blocking substrate access and proteolytic activity. CA-074 displays a Ki of 2–5 nM for cathepsin B, versus 40–200 µM for cathepsins H and L, conferring exceptional selectivity (APExBIO). By preventing cathepsin B–mediated cleavage events, CA-074 interrupts proteolytic cascades involved in extracellular matrix degradation, tumor cell invasion, and neuron-glia signaling. In necroptosis, its inhibition of cathepsin B released after LMP protects cells from MLKL-driven cell death (Liu et al., 2023).

Evidence & Benchmarks

• CA-074 exhibits a Ki of 2–5 nM for cathepsin B and >10,000-fold selectivity over cathepsins H and L (Ki 40–200 µM) (APExBIO).
• Chemical inhibition of cathepsin B with CA-074 protects cells from necroptosis induced by MLKL polymerization and lysosomal membrane permeabilization (Liu et al., 2023, DOI).
• In a 4T1.2 breast cancer mouse model, intraperitoneal injection of CA-074 (50 mg/kg) reduces bone metastasis without affecting primary tumor growth (internal).
• CA-074 suppresses neurotoxic effects of Abeta42-activated microglial cells in vitro and in vivo (internal).
• CA-074 shifts helper T cell responses from Th-2 to Th-1, reducing IgE and IgG1 antibody production (internal).
• CA-074 demonstrates negligible cytotoxicity at 10 mM in cell culture (APExBIO).
• Product is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL, ultrasonic assistance) (APExBIO).

This article extends the mechanistic focus of previous reviews by specifically relating CA-074’s action to MLKL-driven necroptosis and recent advances in regulated cell death pathways.

Applications, Limits & Misconceptions

Applications: CA-074 is routinely used to:

• Dissect cathepsin B–mediated processes in cancer metastasis, especially bone invasion models.
• Study lysosomal membrane permeabilization and necroptosis mechanisms (Liu et al., 2023).
• Modulate neuroinflammation and neuron-glia interactions in neurodegeneration models.
• Investigate immune regulation, especially Th-2/Th-1 helper T cell switching.
• Serve as a benchmark for selectivity and efficacy in cathepsin B research (APExBIO).

Limits: CA-074 does not inhibit serine or aspartic proteases. Its selectivity is limited to cathepsin B, with negligible action on other cathepsins at experimental concentrations. In vivo, CA-074’s short plasma half-life and limited blood-brain barrier penetration constrain some applications. It is best used for acute studies or where local delivery is feasible.

Common Pitfalls or Misconceptions

• CA-074 does not inhibit cathepsin D or serine proteases at any tested concentration.
• Inactive against cathepsins H and L at concentrations below 10 µM.
• Low oral bioavailability; not suitable for chronic systemic dosing.
• Requires ultrasonic assistance for maximal water solubility.
• Should not be confused with CA-074Me, which is a membrane-permeable methyl ester prodrug.

This article clarifies the practical boundaries of CA-074’s selectivity and application, complementing procedural guides such as this workflow-focused tutorial.

Workflow Integration & Parameters

• Solubility: Dissolve in DMSO at >19.17 mg/mL, ethanol at >31.3 mg/mL, or water at >5.91 mg/mL with sonication.
• Storage: Store solid at -20°C; use freshly prepared solutions for experiments.
• Cell Culture: Use at up to 10 mM with minimal cytotoxicity.
• In Vivo: Intraperitoneal injection at 50 mg/kg in mice; monitor for specific endpoints (e.g., bone metastasis, neurotoxicity).
• Controls: Include non-selective or inactive cathepsin inhibitors to validate specificity.
• For comprehensive protocols, see this practical guide, which this article updates by integrating recent necroptosis pathway findings.

Conclusion & Outlook

CA-074, available from APExBIO (SKU A1926), remains the gold standard for selective cathepsin B inhibition in cancer, neurobiology, and immunology research. Its nanomolar potency, high selectivity, and robust in vitro and in vivo benchmarks ensure reliable dissection of cathepsin B–dependent pathways. Recent advances in regulated cell death and immune modulation further underscore CA-074's relevance. Ongoing research will clarify its therapeutic potential and inform next-generation inhibitor development.